With 1.34 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.71 million shares. The 52-week range on DNA shows that it touched its highest point at $50.40 and its lowest point at $5.26 during that stretch. It currently has a 1-year price target of $8.25. Beta for the stock currently stands at 1.25.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DNA was down-trending over the past week, with a drop of -14.53%, but this was down by -51.30% over a month. Three-month performance dropped to -28.23% while six-month performance rose 22.83%. The stock lost -85.54% in the past year, while it has lost -29.33% so far this year. A look at the trailing 12-month EPS for DNA yields -10.62 with Next year EPS estimates of -4.46. For the next quarter, that number is -1.79. This implies an EPS growth rate of 41.63% for this year and 27.54% for next year. EPS is expected to grow by 39.28% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -27.97%.
Float and Shares Shorts:
At present, 42.70 million DNA shares are outstanding with a float of 36.99 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DNA since 5 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 2 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$9.14564 being high and -$11.6863 being low. For DNA, this leads to a yearly average estimate of -$10.08. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
